Top Stories
Gilead accelerates oncology transformation with three rapid acquisitions across CAR-T, TCE, and ADC platforms
Gilead Sciences completed three strategic oncology acquisitions over six weeks, signaling an aggressive push into next-generation cancer therapeutics, according to BioPharma Dive. The deals include Arcellx for BCMA-directed CAR-T cell therapy ($7.8B, February 2026), Ouro Medicines for T-cell engager immunotherapy ($2.2B, March 2026), and Tubulis for antibody-drug conjugate technology ($3.15B upfront plus up to $1.85B in milestones, April 2026). BioPharma Dive reported that Gilead executives framed these acquisitions as essential to their diversification beyond HIV and hepatitis, with up to 10 new launches expected through 2027. The rapid-fire deal strategy positions Gilead against established oncology players like Daiichi Sankyo and AstraZeneca across multiple modalities. According to BioPharma Dive, the timing coincides with increasing ADC valuations across the sector, suggesting Gilead may have paid premium prices to secure competitive positioning. Gilead gains immediate access to three differentiated oncology platforms Competing bidders miss out on scarce ADC and degrader assets
Roche bets $20M on degrader-antibody conjugates as next evolution beyond traditional ADCs
Roche expanded its decade-long partnership with C4 Therapeutics, committing $20M upfront for degrader-antibody conjugates (DACs) that combine protein degradation with targeted delivery, Endpoints News reported. The deal extends C4's proprietary TORPEDO® platform into antibody conjugation, creating hybrid molecules that degrade rather than just inhibit target proteins. According to Endpoints News, this represents Roche's strategic hedge as traditional ADCs face increasing competition and payload limitations. C4 will design degrader payload candidates using TORPEDO®, while Roche will handle antibody design, conjugation, and clinical development. DACs theoretically offer advantages over conventional ADCs by eliminating target proteins entirely rather than blocking function, potentially overcoming resistance mechanisms. The collaboration covers two programs with an option for a third, and C4 is eligible for over $1.0 billion in development, regulatory, and commercial milestones plus tiered royalties, per a C4 Therapeutics press release. The modest upfront payment suggests early-stage technology with significant development risks ahead. Roche secures first-mover advantage in DAC technology Traditional ADC players may face platform obsolescence
FDA delivers second rejection to Replimune melanoma drug despite breakthrough designation
FDA rejected Replimune's oncolytic virus RP1 (in combination with nivolumab) for advanced melanoma on April 10, 2026, marking the second Complete Response Letter for a drug that previously received breakthrough therapy designation, STAT News reported. The CRL indicated that FDA does not consider the IGNYTE trial an adequate and well-controlled investigation providing substantial evidence of effectiveness, citing concerns about heterogeneity of the patient population and tumor assessment methodology. The first CRL was issued in July 2025, and Replimune resubmitted in October 2025 with new analyses. According to STAT News, RP1 became a regulatory flashpoint after FDA initially granted breakthrough status based on Phase 2 IGNYTE data showing a 34% response rate with 24.8-month median duration of response. BioPharma Dive noted the rejection undermines confidence in FDA's breakthrough designation process and raises questions about oncolytic virus viability as a cancer treatment class. The company announced it would substantially scale back U.S. manufacturing operations following the decision, per a Replimune press release. Replimune faces extended timeline and uncertain regulatory path Oncolytic virus class credibility damaged by repeated setbacks
Pipeline Watch
Celltrion's antibody-drug conjugate CT-P71, targeting Nectin-4, received FDA Fast Track designation on April 10, 2026 for locally advanced or metastatic urothelial carcinoma in patients who have received prior therapy, according to CancerNetwork. The designation accelerates development timelines in a cancer type with limited treatment options beyond checkpoint inhibitors and existing ADCs.
The Phase 3 trial evaluating atezolizumab plus chemoradiotherapy in muscle-invasive bladder cancer moved to active but not recruiting status, per ClinicalTrials.gov. The National Cancer Institute-sponsored study tests whether adding immunotherapy improves local control outcomes.
Akari Therapeutics formed a partnership with WuXi XDC to accelerate development and manufacturing of its novel antibody-drug conjugate program, Fierce Biotech reported. The collaboration provides Akari access to established ADC production capabilities in the competitive conjugation space.
Kainova Therapeutics dosed the first patient in the European expansion of its DOMISOL Phase 1/2 trial evaluating antibody-drug conjugate DT-7012, according to Pharmafile. The expansion broadens geographic recruitment for the dose-escalation study in solid tumors.
The Journal of Clinical Oncology published analysis on system-level innovations beyond drug development that are transforming cancer care delivery. The perspective examines how treatment infrastructure and care coordination impact patient outcomes independently of novel therapeutics.
The European Cancer Organisation highlighted persistent disparities in high-quality cancer care access across European countries, per OncoDaily. The initiative focuses on standardizing treatment protocols and reducing geographic variations in survival outcomes for major cancer types.
Competitive Landscape
Gilead's triple acquisition spree—spanning CAR-T, T-cell engagers, and ADCs—and Roche's DAC partnership signal intensifying competition across oncology modalities. Established ADC leaders like Daiichi Sankyo maintain market position Smaller ADC biotechs face acquisition pressure or partnership demands
| Company | ADC Strategy | Recent Move |
|---|---|---|
| Daiichi Sankyo | Market Leader | 3 Approved ADCs |
| Gilead | New Entrant | 3 Oncology Acquisitions (CAR-T, TCE, ADC) |
| Roche | Platform Hedge | DAC Partnership |
| Pfizer | Traditional ADCs | No Recent Moves |
FDA's second rejection of RP1 despite breakthrough designation raises questions about the entire oncolytic virus treatment class. Clinical trial design challenges and regulatory uncertainty around single-arm evidence make investor confidence difficult to rebuild across competing platforms.
Roche's C4 partnership demonstrates growing confidence in targeted protein degradation technology, while Gilead's Ouro acquisition reflects big pharma appetite for novel immunotherapy modalities such as T-cell engagers. Early-stage companies with differentiated oncology platforms are becoming increasingly valuable acquisition targets for big pharma pipelines.
Forward Looking
- Watch for Gilead integration timelines and development priorities across its three new oncology platforms in upcoming earnings calls.
- Roche-C4 DAC candidates entering clinic will test whether degrader-conjugates deliver meaningful advantages over traditional ADC approaches.
- Replimune's response to FDA concerns and potential pivot strategies will influence broader oncolytic virus investment sentiment.
- Additional big pharma ADC consolidation likely as remaining independent platforms become acquisition targets in competitive landscape.